AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Flerie AB

Net Asset Value Jul 5, 2024

6601_rns_2024-07-05_7d70147d-e412-48ef-8a9a-9326ceca752b.pdf

Net Asset Value

Open in Viewer

Opens in native device viewer

NET ASSET VALUE 2024 06 30

On the 30 June 2024 Flerie AB's ("Flerie") Net Asset Value (NAV) was SEK 4,380 million and NAV per share was SEK 0.561.

Allocation of net asset value Share of portfolio
company
Fair value
(MSEK)
Part of NAV per share
(SEK)
Share of
NAV
Product Development
Prokarium 42% 471 0.060 10.8%
Xspray Pharma 17% 461 0.059 10.5%
Empros Pharma 79% 204 0.026 4.7%
KAHR Medical 31% 200 0.026 4.6%
Atrogi 34% 154 0.020 3.5%
Microbiotica 11% 134 0.017 3.1%
Xintela 56% 105 0.013 2.4%
Mendus 24% 103 0.013 2.4%
Geneos Therapeutics 12% 102 0.013 2.3%
Lipum 57% 98 0.013 2.2%
Toleranzia 58% 76 0.010 1.7%
Synerkine Pharma 43% 52 0.007 1.2%
AnaCardio 19% 52 0.007 1.2%
Egetis Therapeutics 2% 34 0.004 0.8%
Buzzard Pharmaceuticals 14% 29 0.004 0.7%
Vitara Biomedical 5% 28 0.004 0.6%
Sixera Pharma 23% 26 0.003 0.6%
Alder Therapeutics 21% 17 0.002 0.4%
Amarna Therapeutics 60% 12 0.001 0.3%
Strike Pharma 14% 6 0.001 0.1%
EpiEndo Pharmaceuticals 10% 0 0.000 0.0%
Total 2,365 0.303 54.0%
Commercial Growth
NorthX Biologics 92% 189 0.024 4.3%
Symcel 31% 169 0.022 3.9%
Nanologica 39% 95 0.012 2.2%
A3P Biomedical 8% 75 0.010 1.7%
Provell Pharmaceuticals 72% 67 0.009 1.5%
Chromafora 32% 53 0.007 1.2%
Frontier Biosolutions 2% 19 0.002 0.4%
Bohus Biotech 45% 17 0.002 0.4%
Total 683 0.088 15.6%
Limited Partnerships, total 76 0.010 1.7%
Assets related to portfolio
companies
376 0.048 8.6%
Other assets and liabilities 879 0.113 20.1%
Net asset value 4,380 0.561 100.0%

For more information:

Ted Fjällman, CEO Email: [email protected]

Flerie in brief

Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie's active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB's ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com

Attachments

NET ASSET VALUE 2024 06 30

Talk to a Data Expert

Have a question? We'll get back to you promptly.